Table 1. Antimicrobial susceptibility results for isolates and type strains included in this study.

Isolates/strains: 1, EPM 10695; 2, EPM 10906^T; 3, IAL 3785; 4, JAN1; 5, JAN2; 6, M. abscessus subsp. abscessus ATCC 19977^T; 7, M. abscessus subsp. bolletti CCUG 50184^T; 8, M. chelonae ATCC 35752^T; 9, M. immunogenum ATCC 700505^T; 10, M. salmoniphilum ATCC 13758^T; 11, M. franklinii DSM 45524^T. r, Resistant; i, intermediate; s, susceptible – criteria for rapidly growing mycobacteria established by CLSI (2011); nd, not determined.

Drug	MIC (μg ml− 1)
	1	2	3	4	5	6	7	8	9	10	11
Amikacin	32 i	128 r	32 i	32 i	32 i	8 s	16 s	8 s	≤ 4 s	16 s	≤ 4 s
Ciprofloxacin	2 i	2 i	4 r	4 r	4 r	4 r	8 r	0.5 s	1 s	1 s	0.5 s
Clarithromycin
3 days	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s
14 days	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	≤ 0.5 s	>64 r	>64 r	≤ 0.5 s	≤ 0.5 s	nd	≤ 0.5 s
Doxycycline	>32 r	>32 r	>32 r	>32 r	>32 r	>32 r	>32 r	4 i	>32 r	>32 r	≤ 0.25 s
Cefoxitin	512 r	>512 r	512 r	>512 r	512 r	64 i	32 i	512 r	256 r	512 r	16 s
Tobramycin	16 r	32 r	16 r	8 r	16 r	8 r	16 r	2 s	4 i	4 i	2 s
Minocycline	32 r	16 r	4 i	16 r	8 r	8 r	16 r	2 i	8 r	2 i	≤ 0.25 s
Moxifloxacin	2 i	8 r	4 r	4 r	2 i	8 r	8 r	≤ 0.25 s	1 s	2 i	1 s